Phaseline

Targets › G6PC1

G6PC1 (Glucose-6-phosphatase catalytic subunit 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Dec 2027.

Hydrolyzes glucose-6-phosphate to glucose in the endoplasmic reticulum. Forms with the glucose-6-phosphate transporter (SLC37A4/G6PT) the complex responsible for glucose production in the terminal step of glycogenolysis and gluconeogenesis. (UniProt, P35575)

Open in Phaseline: the race on G6PC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beam TherapeuticsBEAM-301
In vivo base editor targeting G6PC1 c.247C>T allele via A:T-to-G:C base-pair substitution
G6PC1Phase 1Glycogen Storage Disease Type IaDec 2027

Conditions

Glycogen Storage Disease Type Ia (1)

Modalities

small molecule (1)

Companies

Beam Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.